Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: A phase I study

E. A. Perez, S. A. Scudder, F. A. Meyers, M. S. Tanaka, C. Paradise, D. R. Gandara

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Twenty-nine patients with biopsy-confirmed metastatic melanoma (17) or metastatic renal cell carcinoma (12) were treated with escalating doses of recombinant human interleukin-2 (IL-2) administered as weekly 24-h intravenous infusions. Patients received from 3 to 12 x 106 C.U./m2 (18-72 x 106 I.U./m2) weekly over a treatment period of 1 to 16 weeks, with a median of eight weekly cycles administered. Patients in all treatment groups experienced non-life-threatening systemic side effects consisting of fever, nausea, vomiting, fluid retention, and diarrhea. Grade III hypotension was seen in four of six patients (67%) at 12 x 106 C.U./m2, and represented the dose-limiting toxicity. Grade IV hypotension occurred in 1 of 14 patients at 6 x 106 C.U./m2; no other grade IV toxicities were observed. Grade III fever occurred in 3 of 11 patients(27%) treated at 3 x 106 C.U/m2, 3 of 14 patients (21%) at 6 x 106 C.U./m2, and 3 of 6 patients (50%) at 9 x 106 C.U./m2. An objective response was observed in 3 of 28 evaluable patients (10%): 1 complete response and 1 partial response in renal cell cancer, and 1 partial response in a melanoma-patient. We conclude that for future studies, the recommended dose of IL-2 given as a weekly 24-h infusion is 9 x 106 C.U./m2 and that a low rate of objective tumor response can be obtained in patients with melanoma and renal cell carcinoma using this regimen.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalJournal of Immunotherapy
Volume10
Issue number1
StatePublished - 1991
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Melanoma
Hypotension
Fever
Intravenous Infusions
Nausea
Vomiting
Diarrhea
Biopsy

Keywords

  • interleukin-2
  • metastatic melanoma
  • metastatic renal cell carcinoma
  • phase I study

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Perez, E. A., Scudder, S. A., Meyers, F. A., Tanaka, M. S., Paradise, C., & Gandara, D. R. (1991). Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: A phase I study. Journal of Immunotherapy, 10(1), 57-62.

Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma : A phase I study. / Perez, E. A.; Scudder, S. A.; Meyers, F. A.; Tanaka, M. S.; Paradise, C.; Gandara, D. R.

In: Journal of Immunotherapy, Vol. 10, No. 1, 1991, p. 57-62.

Research output: Contribution to journalArticle

Perez, EA, Scudder, SA, Meyers, FA, Tanaka, MS, Paradise, C & Gandara, DR 1991, 'Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: A phase I study', Journal of Immunotherapy, vol. 10, no. 1, pp. 57-62.
Perez, E. A. ; Scudder, S. A. ; Meyers, F. A. ; Tanaka, M. S. ; Paradise, C. ; Gandara, D. R. / Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma : A phase I study. In: Journal of Immunotherapy. 1991 ; Vol. 10, No. 1. pp. 57-62.
@article{78a2773e384c4a0b8dd518de5a9a5f50,
title = "Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: A phase I study",
abstract = "Twenty-nine patients with biopsy-confirmed metastatic melanoma (17) or metastatic renal cell carcinoma (12) were treated with escalating doses of recombinant human interleukin-2 (IL-2) administered as weekly 24-h intravenous infusions. Patients received from 3 to 12 x 106 C.U./m2 (18-72 x 106 I.U./m2) weekly over a treatment period of 1 to 16 weeks, with a median of eight weekly cycles administered. Patients in all treatment groups experienced non-life-threatening systemic side effects consisting of fever, nausea, vomiting, fluid retention, and diarrhea. Grade III hypotension was seen in four of six patients (67{\%}) at 12 x 106 C.U./m2, and represented the dose-limiting toxicity. Grade IV hypotension occurred in 1 of 14 patients at 6 x 106 C.U./m2; no other grade IV toxicities were observed. Grade III fever occurred in 3 of 11 patients(27{\%}) treated at 3 x 106 C.U/m2, 3 of 14 patients (21{\%}) at 6 x 106 C.U./m2, and 3 of 6 patients (50{\%}) at 9 x 106 C.U./m2. An objective response was observed in 3 of 28 evaluable patients (10{\%}): 1 complete response and 1 partial response in renal cell cancer, and 1 partial response in a melanoma-patient. We conclude that for future studies, the recommended dose of IL-2 given as a weekly 24-h infusion is 9 x 106 C.U./m2 and that a low rate of objective tumor response can be obtained in patients with melanoma and renal cell carcinoma using this regimen.",
keywords = "interleukin-2, metastatic melanoma, metastatic renal cell carcinoma, phase I study",
author = "Perez, {E. A.} and Scudder, {S. A.} and Meyers, {F. A.} and Tanaka, {M. S.} and C. Paradise and Gandara, {D. R.}",
year = "1991",
language = "English (US)",
volume = "10",
pages = "57--62",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma

T2 - A phase I study

AU - Perez, E. A.

AU - Scudder, S. A.

AU - Meyers, F. A.

AU - Tanaka, M. S.

AU - Paradise, C.

AU - Gandara, D. R.

PY - 1991

Y1 - 1991

N2 - Twenty-nine patients with biopsy-confirmed metastatic melanoma (17) or metastatic renal cell carcinoma (12) were treated with escalating doses of recombinant human interleukin-2 (IL-2) administered as weekly 24-h intravenous infusions. Patients received from 3 to 12 x 106 C.U./m2 (18-72 x 106 I.U./m2) weekly over a treatment period of 1 to 16 weeks, with a median of eight weekly cycles administered. Patients in all treatment groups experienced non-life-threatening systemic side effects consisting of fever, nausea, vomiting, fluid retention, and diarrhea. Grade III hypotension was seen in four of six patients (67%) at 12 x 106 C.U./m2, and represented the dose-limiting toxicity. Grade IV hypotension occurred in 1 of 14 patients at 6 x 106 C.U./m2; no other grade IV toxicities were observed. Grade III fever occurred in 3 of 11 patients(27%) treated at 3 x 106 C.U/m2, 3 of 14 patients (21%) at 6 x 106 C.U./m2, and 3 of 6 patients (50%) at 9 x 106 C.U./m2. An objective response was observed in 3 of 28 evaluable patients (10%): 1 complete response and 1 partial response in renal cell cancer, and 1 partial response in a melanoma-patient. We conclude that for future studies, the recommended dose of IL-2 given as a weekly 24-h infusion is 9 x 106 C.U./m2 and that a low rate of objective tumor response can be obtained in patients with melanoma and renal cell carcinoma using this regimen.

AB - Twenty-nine patients with biopsy-confirmed metastatic melanoma (17) or metastatic renal cell carcinoma (12) were treated with escalating doses of recombinant human interleukin-2 (IL-2) administered as weekly 24-h intravenous infusions. Patients received from 3 to 12 x 106 C.U./m2 (18-72 x 106 I.U./m2) weekly over a treatment period of 1 to 16 weeks, with a median of eight weekly cycles administered. Patients in all treatment groups experienced non-life-threatening systemic side effects consisting of fever, nausea, vomiting, fluid retention, and diarrhea. Grade III hypotension was seen in four of six patients (67%) at 12 x 106 C.U./m2, and represented the dose-limiting toxicity. Grade IV hypotension occurred in 1 of 14 patients at 6 x 106 C.U./m2; no other grade IV toxicities were observed. Grade III fever occurred in 3 of 11 patients(27%) treated at 3 x 106 C.U/m2, 3 of 14 patients (21%) at 6 x 106 C.U./m2, and 3 of 6 patients (50%) at 9 x 106 C.U./m2. An objective response was observed in 3 of 28 evaluable patients (10%): 1 complete response and 1 partial response in renal cell cancer, and 1 partial response in a melanoma-patient. We conclude that for future studies, the recommended dose of IL-2 given as a weekly 24-h infusion is 9 x 106 C.U./m2 and that a low rate of objective tumor response can be obtained in patients with melanoma and renal cell carcinoma using this regimen.

KW - interleukin-2

KW - metastatic melanoma

KW - metastatic renal cell carcinoma

KW - phase I study

UR - http://www.scopus.com/inward/record.url?scp=0025978347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025978347&partnerID=8YFLogxK

M3 - Article

C2 - 2012799

AN - SCOPUS:0025978347

VL - 10

SP - 57

EP - 62

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 1

ER -